60 results about "Inflammation mediators" patented technology

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the use of an inflammatory disease using the lignan compound. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-a. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

The present invention relates to the usage of wilfordii chlorine lactonic alcohol T4 for curing neural immune inflammatory diseases and provides a new usage of the wilfordii chlorine lactonic alcohol T4 for curing neural immune inflammatory diseases caused by the neural toxicity of microglia-mediated ABeta1-42 and LPS. The traditional medicine monomer of the wilfordii chlorine lactonic alcohol T4 has the following functions: obviously reducing the toxic damages of the oligmeric ABeta1-42 and LPS-induced gel-inflammation reaction on nerve cells, so as to protect the survival of nerve cells; inhibiting the level of inflammation medium produced by the oligmeric ABeta1-42 and the LPS-induced microglia cells; inhibiting the increase of iNOS and COX-2 expression of the oligmeric ABeta1-42 and the LPS-induced microglia cells; inhibiting the activation of NF-KappaB and JNK signal access of the oligmeric ABeta1-42 and the LPS-induced microglia cells. Therefore, the present invention provides direct powerful experimental evidence and theoretical basis for the application of the wilfordii chlorine lactonic alcohol T4 in neural immune inflammatory diseases, especially prevention and treatment of Alzheimer disease, thus having strong scientificity and creativity, as well as high development and application value.

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or a pharmaceutically acceptable salt thereof. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-α and by treating or preventing inflammatory disease in vivo. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

The invention relates to N-alkylglycine trimeres (I), wherein R1 represents 2-(2,4-dichlorophenyl)ethyl, 3-methyl-butyl, 2-(methylcarbonylamino)ethyl, 2-(N-imidazolyl)ethyl or 3-(N,N-dimethylamino)propyl; R2 represents 2-(2,4-dichlorophenyl)ethyl, 2-(4-methoxyphenyl)ethyl, 3,3-diphenylpropyl or 3-(N,N-diethylamino)propyl; and R3 represents N,N-diethylaminopropyl, 3,3-diphenyl-propyl or 2-[2-(N-methyl)pyrrolidinyl]ethyl. Said trimeres are capable of blocking the ionic channels that are activated by exogenous chemical substances, heat stimuli or inflammation mediators, such as nociceptors VR1 and glutamate ionotropic receptors and are useful for treating disorders mediated by the activity of said receptors.

The invention provides mature peptide of a myotis brandti leukotriene A4 hydrolase inhibitor Motistin and an application of the mature peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the mature peptide is shown as SEQ ID NO: 2. The invention discovers for the first time that the mature peptide of Motistin can inhibit the hydrolase activity of LTA4H without affecting the aminopeptidase activity of LTA4H. The mature peptide of Motistin can target LT44H, can inhibit the recruitment of immune cells and the generation of inflammatory mediators by inhibiting the hydrolase activity of LTA4H, and also has the function of inhibiting the generation of inflammatory cytokines IL6, TNF <alpha> and IL1<beta> caused by virus and bacterial lipopolysaccharide.The mature peptide has the potential of becoming an effective drug for inhibiting inflammation.

The invention discloses application of epoxydiene taken as an inhibitor of proinflammatory mediators, and relates to a compound, namely the epoxydiene, in particular to application of the epoxydiene taken as the inhibitor of the proinflammatory mediators in medical field. The invention provides the application of the epoxydiene taken as the inhibitor of the proinflammatory mediators, in particular application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as endotoxin shock and the like, and application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as rheumatoid arthritis and the like. A pharmacological experiment proves that the epoxydiene has important adjustment effect on the processes of inflammations by inhibiting the expression of a plurality of the proinflammatory mediators, and can be used for preparing anti-inflammatory medicaments. The compound can be obtained by separating from fungus fermentation products, and can also be chemically synthesized.

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the use of an inflammatory disease using the lignan compound. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-α. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

Stable, topically applicable water-in-oil emulsions, well suited for therapeutically treating irritated / sensitive skins and having high electrolyte content, comprise (a) at least 2% by weight of at least one water-soluble metal salt, (b) at least one hydrophobic gelling agent, (c) less than 5% by weight of at least one emulsifying agent, and, advantageously, at least one biologically active agent, for example an active agent that modulates skin differentiation and / or proliferation and / or pigmentation, an anti-inflammatory, an antibacterial, an antifungal, etc., and / or at least one keratolytic active agent, neuropeptide antagonist and / or inflammation-mediator antagonist.

The invention relates to a method for manufacturing phenolic acid positions of vernonia anthelmintica and anti-inflammation application of the phenolic acid positions. The method includes smashing dried fruits of the vernonia anthelmintica; extracting extracts by the aid of organic solvents; separating and purifying the extracts by the aid of resin to obtain the phenolic acid positions of the vernonia anthelmintica. Main active ingredients of phenolic acid at the positions of the vernonia anthelmintica include 3, 4-dicaffeoyl-quinic acid, 3, 5-dicarffeoyl-quinic acid and 4, 5-dicaffeoyl-quinic acid, the total content of the phenolic acid ranges from 20% to 99%, excess release of nitric oxide of inflammation mediators can be obviously suppressed by the phenolic acid positions of the vernonia anthelmintica in inflammation response of mice macrophage RAW264.7 induced by lipopolysaccharide, excessive secretion of interleukin 6, interleukin 1 and tumor necrosis factors alpha of inflammation factors can be suppressed, excess expression of nitric oxide synthase and epoxidase 2 can be suppressed, and phosphorylation of nuclear factors kB can be suppressed. The method has the advantages that the phenolic acid positions of the vernonia anthelmintica has excellent anti-inflammation activity and can be used for preventing or treating inflammation due to the excess nitric oxide, the excess tumor necrosis factors alpha, the excess interleukin 6 or the excess interleukin 1.

Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases.

The present invention relates to vesicles derived from the genus Bacillus bacteria and a use thereof. The present inventors have confirmed that the vesicles are significantly reduced in samples of patients with cancers, such as liver cancer, bladder cancer, breast cancer, and ovarian cancer; inflammatory diseases, such as asthma and atopic dermatitis; or metabolic diseases, such as diabetes and cirrhosis, compared with normal persons, and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, such as E. coli-derived vesicles, which are causative factors of inflammatory diseases, diabetes, and the like. Therefore, the vesicles derived from the genus Bacillus bacteria according to the present invention can be advantageously used for the purpose of developing adiagnostic method for cancer, inflammatory diseases, and metabolic diseases, and a preventive or therapeutic composition therefor.

The invention encompasses compositions and methods for effectively treating and / or preventing the development and / or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and / or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts. The inventive compositions used for administration to human and other mammalian subjects having or at risk for development of osteoporosis comprise (1) at least one agent capable of modulating expression and / or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT / enhancer binding protein-α (C / EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent that activates expression and / or activity of one or more of the osteogenic transcription factors (Runx2 / Cbfα1, Dlx5, Osterix, Msx2); (3) at least one agent that activates expression and / or activity of one or more of bone morphogenetic proteins (BMPs: BMP 2 and 4), alkaline phosphatase (ALP), and osteocalcin; (4) at least one agent capable of activating Wnt / β-catenin signaling pathway; (5) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (6) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); and (7) at least one agent that induces the expression of and / or activates one or more of adenosine monophosphate-activated protein kinase (AMPK), sirtuin (SIRT1) and adiponectin (AP).

This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and / or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit / suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

The invention relates to an application of a compound isatis root preparation in preparing drugs for preventing and curing endotoxaemia. The compound isatis root preparation is composed of isatis root and dyers woad leaf. Through a plurality of evaluation experiments in pharmaco dynamics, the isatis root granules show broad anti-endotoxaemia activity in vitro and in vivo, which can directly neutralize and degrade the endotoxaemia and remarkably antagonize fever, lethality and DIC biological effect resulted from endotoxaemia. At the same time, the molecular biology experiment indicates that the preparation of the invention can inhibit the endotoxaemia to stimulate the expression of the important tissue moesin mRNA of human body and ease the rising degree of P38 MAPK. Moreover, the isatis root granules can inhibit the composition and release of endotoxaemia-induced inflammations, lower the LPO level, heighten the SOD activity, alleviate the damages of human body resulted from being attracted by free radicals, which is favorable for inhibiting inflammatory response syndromes, thus effectively controlling the state of illness and death rate.

The invention is compositions and methods for determining the presence of one or more immune response mediators, comprising obtaining a solution containing polymorphonuclear neutrophils, exposing the neutrophils to a chromophore, allowing the chromophore to oxidize to form a luminescent compound, and measuring the level of visible or ultraviolet radiation.

A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and / or inflammation is implicated.

The invention relates to application of scopoletin to inhibition of neuroinflammation and prevention and / or treatment of acute and chronic neurodegenerative diseases caused by the neuroinflammation, and in particular relates to application of the scopoletin to preparation of a medicine for inhibiting the neuroinflammation. The invention proves that the scopoletin has the remarkable neuroinflammation inhibition activity through a pharmacological experiment for the first time, and the scopoletin can be used for preparing the medicine for preventing and / or treating the neuroinflammation and related diseases, so that the scopoletin has relatively high clinical application value and development prospect. The invention provides novel application of the scopoletin to the inhibition of the neuroinflammation. The pharmacological experiment proves that the scopoletin can be used for remarkably inhibiting releasing of LPS (Lipopolysaccharide) induced microglial cell inflammation mediators NO, ROS(Reactive Oxygen Species), TNF-alpha (Tumor Necrosis Factor-alpha) and IL-1beta (Interleukin-1beta), and has the remarkable neuroinflammation inhibition activity. Therefore, the compound can be usedfor preparing the medicine for preventing and / or treating the neuroinflammation and related central nervous degenerative diseases.

The invention relates to application of scopolin to inhibition of neuroinflammation and prevention and / or treatment of acute and chronic neurodegenerative diseases caused by the neuroinflammation, andin particular relates to application of the scopolin to preparation of a medicine for inhibiting the neuroinflammation. The invention proves that the scopolin has the remarkable neuroinflammation inhibition activity through a pharmacological experiment for the first time, and the scopolin can be used for preparing the medicine for preventing and / or treating the neuroinflammation and related diseases, so that the scopolin has relatively high clinical application value and development prospect. The invention provides novel application of the scopolin to the inhibition of the neuroinflammation.The pharmacological experiment proves that the scopolin can be used for remarkably inhibiting releasing of LPS (Lipopolysaccharide) induced microglial cell inflammation mediators NO, ROS (Reactive Oxygen Species), TNF-alpha (Tumor Necrosis Factor-alpha) and IL-1beta (Interleukin-1beta), and has the remarkable neuroinflammation inhibition activity. Therefore, the compound can be used for preparingthe medicine for preventing and / or treating the neuroinflammation and related central nervous degenerative diseases, and has the clinical application value and development prospect.

The invention relates to the field of biomedicines, and concretely relates to a recombinant protein function structure domain and a use thereof in inhibition of macrophage tissue factor expression. In the invention, up-regulation of TF (tissue factor) expression by oxLDL is confirmed, the up-regulation is realized through starting signal regulation under the mediation of LOX-1, a recombinant beta2-GPIDV can inhibit oxLDL induced TF and LOX-1 expression, and intervention of combination of the oxLDL and the LOX-1 is proved through a flow cytometer method by adopting an autonomously constructed expression human LOX-1 gene 293T cell model in order to block out expression of downstream TF and LOX-1. The combination of the OxLDL and the LOX-1 induces TF expression to initiate thrombus, and also initiates endothelial cell dysfunction to generate an inflammation medium, and is important to form and develop atherothrombosis, so the potential treatment effect of the recombinant beta2-GPIDV in the atherothrombosis diseases is displayed in the invention.

The invention belongs to the technical field of medicine, and provides novel phenylpropanoid compounds extracted from praxelis clematidea. An animal pharmacodynamic test shows that the novel phenylpropanoid compounds exhibit an inhibitory effect on inflammatory medium NO produced by LPS-induced BV-2 cells, and have a significant anti-inflammatory effect and no toxicity to the cells, so that the praxelis clematidea phenylpropanoid compounds provided by the invention can be used to prepare drugs related to inflammation.

The invention discloses a medicine for treating pityriasis rosea. The medicine comprises an externally used medicine and an internally used medicine, wherein the externally used medicine is prepared from spartina alterniflora loisel extract and fructus hippophae extract; the internally used medicine is prepared from wheat germ, corn germ, radix peucedani and fructus citri. According to the medicine disclosed by the invention, through comprehensive use of the internally used medicine and the externally used medicine, a synergistic effect is generated; after enzymolysis is carried out on traditional Chinese medicine, mast cells can be stabilized, and degranulation of the mast cells can be inhibited, so that release of inflammation mediators can be inhibited, the activity of eosinophilic granulocyte can be directly inhibited, and the medicine has the characteristics that the anti-histamine treatment effect is high and the effects are quickly obtained; meanwhile, the taste is greatly improved; the externally used medicine is prepared from the spartina alterniflora loisel extract and the fructus hippophae extract, and by wiping the externally used medicine on a wound of the pityriasis rosea, anti-inflammatory and anti-allergy functions are obtained, and meanwhile, protective acidic cortex in skin is facilitated to be stabilized; by matching with the internally used medicine orally, the treatment effect on the pityriasis rosea is obvious.

T6 and T11 are based, a mutational peptide library is constructed by adopting an NNK strategy, MD-2 (myeloid differential protein 2) full-length protein is used as target protein, and the mutational peptide library is subjected to affinity selection, so as to realize high-affinity phage clone. Through cell factor generation inhibiting experiment and detection of expression of inflammatory medium in animal serum, the fact that fusion peptide shown in one phage clone can simulate anti-inflammatory polypeptide of MD-2 is discovered, and the amino acid sequence of the anti-inflammatory polypeptide is KRKMRMNTRRL. The combination of the anti-inflammatory polypeptide and MD-2 full-length protein is higher than original T6 and T11 clone, the possibility that lipopolysaccharide (LPS) stimulates macrophage to synthesize and release inflammatory medium can be obviously reduced, and the anti-inflammatory effect is obviously higher than that of original polypeptide.

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.